Literature DB >> 33180255

Synthesis, characterization and biological evaluation of octyltrimethylammonium tetrathiotungstate.

Karla Vega-Granados1, Juan Cruz-Reyes1, José F Horta-Marrón1, Manuel Marí-Beffa2, Laura Díaz-Rubio1, Iván Córdova-Guerrero1, Daniel Chávez-Velasco3, M Carmen Ocaña4, Miguel A Medina4, Lilian B Romero-Sánchez5.   

Abstract

Octyltrimethylammonium tetrathiotungstate salt (ATT-C8) was synthesized and its ability to chelate copper was evaluated. The biological and toxic aspects were evaluated by in vitro and in vivo assays, using bovine aorta endothelial cells (BAEC) and zebrafish (Danio rerio) embryos. The obtained results suggest that ATT-C8 has better biocompatibility, showing a significantly lower lethal concentration 50 (LC50) value in comparison to ammonium tetrathiotungstate (ATT). Zebrafish embryos assay results indicate that both tetrathiotungstate salts at the studied concentrations increase the hatching time. Even more, an in vivo assay showed that synthesized materials behave as copper antagonists and have the ability to inhibit its toxicological effects. Also, both materials were found to be active for the in vitro 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay. The characterization of the materials was carried out using the following spectroscopic techniques: Ultraviolet-Visible (UV-Vis), Fourier Transform Infrared (FTIR) and proton nuclear magnetic resonance (1H-NRM).

Entities:  

Keywords:  Anticopper therapy; Antioxidant activity; Tetrathiotungstate salts; Toxicity; Zebrafish embryo

Mesh:

Substances:

Year:  2020        PMID: 33180255     DOI: 10.1007/s10534-020-00267-9

Source DB:  PubMed          Journal:  Biometals        ISSN: 0966-0844            Impact factor:   2.949


  15 in total

1.  Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.

Authors:  G J Brewer; R D Dick; D K Grover; V LeClaire; M Tseng; M Wicha; K Pienta; B G Redman; T Jahan; V K Sondak; M Strawderman; G LeCarpentier; S D Merajver
Journal:  Clin Cancer Res       Date:  2000-01       Impact factor: 12.531

2.  Evaluation of the anti-angiogenic effect of aloe-emodin.

Authors:  C Cárdenas; A R Quesada; M A Medina
Journal:  Cell Mol Life Sci       Date:  2006-12       Impact factor: 9.261

Review 3.  Fishing anti(lymph)angiogenic drugs with zebrafish.

Authors:  Melissa García-Caballero; Ana R Quesada; Miguel A Medina; Manuel Marí-Beffa
Journal:  Drug Discov Today       Date:  2017-10-31       Impact factor: 7.851

Review 4.  Zebrafish: a model system for the study of human disease.

Authors:  K Dooley; L I Zon
Journal:  Curr Opin Genet Dev       Date:  2000-06       Impact factor: 5.578

5.  Stages of embryonic development of the zebrafish.

Authors:  C B Kimmel; W W Ballard; S R Kimmel; B Ullmann; T F Schilling
Journal:  Dev Dyn       Date:  1995-07       Impact factor: 3.780

Review 6.  Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer.

Authors:  George J Brewer
Journal:  Curr Cancer Drug Targets       Date:  2005-05       Impact factor: 3.428

Review 7.  Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.

Authors:  George J Brewer
Journal:  Metallomics       Date:  2009-04-16       Impact factor: 4.526

8.  Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients.

Authors:  G J Brewer; R D Dick; V Johnson; Y Wang; V Yuzbasiyan-Gurkan; K Kluin; J K Fink; A Aisen
Journal:  Arch Neurol       Date:  1994-06

9.  Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy.

Authors:  G J Brewer; V Johnson; R D Dick; K J Kluin; J K Fink; J A Brunberg
Journal:  Arch Neurol       Date:  1996-10

10.  Initial therapy of patients with Wilson's disease with tetrathiomolybdate.

Authors:  G J Brewer; R D Dick; V Yuzbasiyan-Gurkin; R Tankanow; A B Young; K J Kluin
Journal:  Arch Neurol       Date:  1991-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.